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KEY POINTS: 1 
• Endoglin regulatory elements target hemogenic mesoderm and hemogenic 2 
endothelium 3 
• Hemogenic progenitors can be enriched using these elements as molecular probes to 4 
discover novel regulators of hematopoiesis 5 
  6 
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ABSTRACT  1 
Enhancers are the primary determinants of cell identity and specific promoter/enhancer 2 
combinations of Endoglin (ENG) have been shown to target blood and endothelium in the 3 
embryo.  Here, we generated a series of embryonic stem cell lines, each targeted with reporter 4 
constructs driven by specific promoter/enhancer combinations of ENG, to evaluate their 5 
discriminative potential and value as molecular probes of the corresponding transcriptome.  6 
The Eng promoter (P) in combination with the -8/+7/+9kb enhancers, targeted cells in FLK1 7 
mesoderm that were enriched for blast colony forming potential, whereas the P/-8kb enhancer 8 
targeted TIE2+/c-KIT+/CD41- endothelial cells that were enriched for hematopoietic 9 
potential. These fractions were isolated using reporter expression and their transcriptomes 10 
profiled by RNA-seq. There was high concordance between our signatures and those from 11 
embryos with defects at corresponding stages of hematopoiesis.  Of the six genes that were 12 
up-regulated in both hemogenic mesoderm and hemogenic endothelial fractions targeted by 13 
the reporters, LRP2, a multiligand receptor, was the only gene that had not previously been 14 
associated with hematopoiesis. We show that LRP2 is indeed involved in definitive 15 
hematopoiesis and by doing so validate the use of reporter gene coupled enhancers as probes 16 
to gain insights into transcriptional changes that facilitate cell fate transitions. 17 
 18 
  19 
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INTRODUCTION 1 
With advances in microscopy and histology, different cell types can now readily be 2 
distinguished from one another.  However, the molecular characteristics that make each cell 3 
type unique and help distinguish stem cells from their more differentiated progeny in a tissue, 4 
are still obscure.  Harvesting pure populations of stem cells is a pre-requisite to probing their 5 
molecular identity. Over the years, protocols combining flow cytometry with single cell serial 6 
transplantation assays have been progressively refined to purify mouse and human adult 7 
hematopoietic stem cells (HSCs)1,2.  8 
 9 
One of the utilitarian benefits of determining the molecular fingerprint of a HSC is 10 
that it could serve as a measurable goal when developing protocols aimed at generating HSCs 11 
from differentiated cells3.  The failure of current protocols to generate long-term repopulating 12 
HSCs from ES/iPS cells is attributed in part to our incomplete understanding of the 13 
developmental journey that mesodermal progenitors traverse in the embryo when generating 14 
the complement of HSCs that are resident in the bone marrow of a newborn4. Determining 15 
the molecular identities of embryonic HSC precursors is complicated by the lack of 16 
consensus regarding the precise HSC intermediates in the embryo, functional assays that are 17 
less than ideal for assessment of these intermediates and knowledge that these intermediates 18 
are transitory cell populations that are present in very small numbers5.  FLK1 expressing 19 
mesodermal cells in the posterior primitive streak when isolated from the embryo and 20 
cultured in vitro generate blast colonies that have blood, endothelial and vascular smooth 21 
muscle potential6. Blast colony forming cell (BL-CFC) potential in FLK1+ mesoderm has 22 
been estimated to be ~1:3007.  Hemogenic potential in TIE2+c-KIT+ hemogenic endothelial 23 
or VE-CAD+CD45-CD41- pre-HSC cells in the dorsal aorta that transit to hematopoietic 24 
cells range from 1:100-300 8-10. These functional estimates are too low to probe the molecular 25 
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identities of either the early hemangioblast or hemogenic endothelial cell populations in the 1 
developing embryo using currently available protocols. 2 
 3 
Cell identity is encoded within the sequences of tissue specific gene regulatory 4 
elements that direct and coordinate gene expression in a cell11.  A number of regulatory 5 
elements of hematopoietic transcription factors have previously been shown to direct reporter 6 
expression to developing blood cells in the mouse embryo and include enhancers of Scl, 7 
Runx1, Gata2, Erg, Fli1, Lmo2 and Lyl1, which also form a recursive circuit in human adult 8 
HSCs12.  The Runx1+23 enhancer marks a population of early hemogenic endothelial cells 9 
that transit to HSCs and has been used to isolate cells from different embryonic stages for 10 
transcriptomic analysis13. Ly6a/Sca1 and Endoglin (Eng; CD105) serve as useful cell surface 11 
markers for isolation of murine HSC fractions14,15. The promoter of Ly6a and 12 
promoter/enhancer combinations of Eng also target embryonic hematopoiesis and in the case 13 
of the former have been used in conjunction with a reporter to isolate hemogenic endothelial 14 
cells and HSCs from early embryos16-18. 15 
 16 
ENG is an accessory receptor and modulator of TGF-β superfamily signaling19.  ENG 17 
is expressed on FLK1+ mesoderm and is required for normal BL-CFC development and its 18 
expression facilitates the hematopoietic program in these cells10,20.  ENG null mice die at 19 
E9.5 with vascular defects due to abnormal endothelial and pericyte development21.  It is also 20 
a marker of adult murine HSCs that was identified using a Scl+19 driven fluorescent reporter 21 
coupled with transcriptomic and proteomic assessment of purified cells15.  An emerging 22 
concept of developmental hematopoiesis posits that HSC development from the dorsal aorta 23 
at E10 reflects maturation of cells that were fated earlier during embryogenesis towards the 24 
hematopoietic lineage13.  As such we rationalised that transcriptional regulation of ENG, 25 
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which is functionally important for the development of hematopoietic intermediates could be 1 
instructive in helping elucidate the transcriptional environment of these cells. We have 2 
previously shown that sequence information within the promoter and hemato-endothelial 3 
enhancers of Eng determine how reporter genes are targeted to either endothelial or blood and 4 
endothelial tissues in the embryo17,22.  Given the spectrum of cell types that are involved in 5 
the developmental journey of embryonic HSCs and the deterministic role that ENG plays in 6 
their development, we hypothesised that distinct combinations of promoter/enhancers of this 7 
gene are used by different hematopoietic intermediates to regulate ENG expression. We 8 
rationalised that if distinct promoter/enhancer constructs indeed targeted functionally distinct 9 
hematopoietic intermediates, they could be used as molecular probes to profile the 10 
transcriptional environment of these cells. 11 
 12 
Here we show using ES cells with single copy reporter coupled transgenes targeted to 13 
the constitutively active HPRT locus that distinct  promoter/enhancer combinations of ENG 14 
are used by FLK1+ mesoderm and hemogenic endothelium that are enriched for BL-CFC and 15 
hematopoietic potential respectively. Using these reporter coupled transgenes as probes to 16 
harvest cell populations from ESC differentiation assays, we performed RNA-seq to identify 17 
gene sets that were associated with functional enrichment of hematopoietic potential and 18 
show their complementarity with primary mouse tissues at matching stages of development.   19 
Of the six genes that were up-regulated in both hemogenic mesoderm and hemogenic 20 
endothelial fractions targeted by the reporters, LRP2, a multiligand receptor, was the only 21 
gene that had not previously been associated with hematopoiesis. Here, we show that LRP2 is 22 
indeed involved in definitive hematopoiesis and by doing so validate the use of reporter gene 23 
coupled enhancers as a discovery tool. 24 
  25 
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MATERIALS AND METHODS 1 
Murine ES cell culture  2 
The Bry/GFP7 and HM1 ES cells23  were cultured as previously described. See Supplemental 3 
data 4 
 5 
Generating Hprt targeting constructs 6 
To generate the Hprt targeting constructs DNA fragments corresponding to the Eng -8, P, +7, 7 
+ 17,22, mutant +7 (+7Δ, mutant Gata), and mutant +9 (+9Δ, mutant Ets) regions (Fig. S1B) 8 
along with the LacZ reporter gene were ligated in multiple combinations into the pMP8 9 
targeting vector. See Supplemental data 10 
 11 
Hprt targeting of HM1 ES cells 12 
To prepare the cells for targeting, HM1 ES cells were cultured in DMEM-ES medium 13 
containing 1× 6-Thioguanine (6-TG, Sigma Aldrich) for a week before electroporation.  See 14 
Supplemental data. Genomic DNA was extracted and analysed for successful recombination 15 
by PCR and southern blots. 16 
 17 
Isolation of Genomic DNA 18 
Genomic DNA isolated from recombinant ES cell clones was analysed for successful 19 
integration of the DNA fragments by qPCR using primers listed in Supplemental data. 20 
 21 
Southern blotting 22 
10µg of genomic DNA was digested with Hpa1 and Sac1 (NEB) at 37°C O/N and blotted as 23 
detailed in Supplemental data 24 
 25 
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ES cell differentiation into EBs 1 
To generate EBs, ES cells were collected and cultured as detailed in Supplemental data. Cells 2 
were then seeded on ultra-low attachment 60mm plates (Sterilin) and placed in an incubator 3 
at 37°C and 5%CO2. These culture conditions were optimal for growth of day 1-4 EBs 24. 4 
 5 
LacZ staining  6 
Fluorescein di-β-D-galactopyranoside (FDG, Sigma Aldrich) was added to the cells at a 1:1 7 
ratio and incubated at 37C for 1 min. The cell suspension was then added to IMDM/20%FBS 8 
and placed on ice for 1 hour. Further staining with primary and secondary antibodies was 9 
performed after the LacZ staining procedure.  See Supplemental data 10 
 11 
Flow cytometry and cell sorting 12 
Cells were collected from EBs and liquid blast cultures and dissociated into a single cell 13 
suspension. Details of procedure and antibodies are listed in Supplemental data 14 
 15 
Methylcellulose blast colony forming (BL-CFC) assay  16 
2x104 FLK1+/LacZ- and FLK1+/LacZ+ cells sorted from day 3 EBs were seeded in 17 
methylcellulose mix. The blast potential in Flk1+ cells was assayed in triplicate dishes of 18 
1ml. The plates were then placed in a humidified incubator 37°C and 5% CO2. Colonies were 19 
scored following four days of culture24. See Supplemental data 20 
 21 
Liquid BL-CFC assay 22 
Day 3 EBs were dissociated into single cells using trypsin (Gibco), and stained with a Flk1-23 
PE or Flk1-bio antibody (eBiosciences). Sorted FLK1+ cells were seeded on gelatin coated 24 
plates at a density of 7.5-8.5x104 cells/9.6cm2 (in a humidified incubator 37°C, 5% CO2). The 25 
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culture medium consisted of IMDM supplemented with 10% FBS pre-tested for 1 
differentiation, 1% L-Glutamine, 0.6% of 30mg/ml transferrin, 0.3% of 0.15M MTG, 0.5% of 2 
5mg/ml ascorbic acid, 15% D4T conditioned medium, 0.1% of 5µg/ml VEGF, and 0.1% of 3 
10µg/ml IL-6 (R&D systems).  4 
 5 
Hematopoietic methylcellulose colony-forming assay 6 
Cells isolated from day 2 or 4 of liquid blast cultures and seeded for CFU-C assays as 7 
detailed in Supplemental data. Primitive colonies were scored after 4-5 days of culture, 8 
whereas most definitive colonies were scored after 7-10 days. All cytokines used in this assay 9 
were purchased from R&D systems24. 10 
 11 
RT-PCR 12 
List of primers and methods are in Supplemental data. 13 
 14 
Chromatin immunoprecipitation (ChIP) assay 15 
ChIP assays were performed as detailed previously22.  See Supplemental data for a list of 16 
primers and experimental details. 17 
 18 
Mouse embryo immunostaining and imaging 19 
10um thick cryosections of E10.5 fixed mouse embryos embedded in a gelation/sucrose 20 
solution were thawed and rehydrated in PBS prior to immunostaining.  Details of procedure 21 
and antibodies are listed in Supplemental data. 22 
 23 
Generating zebrafish morpholinos and analysis 24 
Details are listed in Supplemental data. 25 
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 1 
Statistical analysis 2 
RT-PCR data, BL-CFCs and hematopoietic colony counts were statistically analysed using 3 
Student’s T-test or Paired Student’s T-test. Significant differences are marked * for p<0.05, 4 
** for p<0.01, *** for p<0.001 and not significant differences are marked NS.  5 
 6 
RNA sequencing and analysis 7 
RNA was isolated from cells as per standard method (For details about samples refer to 8 
supplementary table S3), and amplified using the Ovation RNA amplification system V2 9 
(Nugen).  Single-stranded TruSeq cDNA libraries were generated and sequenced using the 10 
Illumina HiSeq2000 analyzer (BGI, Hong Kong).  The data has been deposited in GEO under 11 
the accession number GSE77390. See Supplemental data for details. 12 
 13 
Pathway and Gene-set enrichment analysis 14 
The Ingenuity IPA Core Analysis Tool (version 17199142) was used to establish ‘Molecular 15 
and Cellular Functions’ that correlate with the lists of differentially expressed genes. Gene-16 
set enrichment analysis was performed using the GSEA Java Desktop tool (v 2.0.13). See 17 
Supplemental data for details. 18 
  19 
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RESULTS 1 
Mesoderm to hemangioblast transition is accompanied by increased Eng expression and 2 
chromatin accessibility at hemato-endothelial regulatory elements.  The promoter of 3 
ENG when coupled with -8kb, +7kb and +9kb enhancers have previously  been shown to 4 
direct reporter expression to either endothelial or blood and endothelial tissues in the embryo 5 
(Figure 1A; 17,22). The Bry-GFP ESC line has been used extensively to investigate the 6 
developmental progression of pre-mesoderm (GFP-/FLK1-) to pre-hemangioblast mesoderm 7 
(GFP+/FLK1-; G+/F-) to the hemangioblast (GFP+/FLK1+; G+F+)7 (Figure 1B).  We used 8 
this cell line to first evaluate expression of Eng and chromatin accessibility at hemato-9 
endothelial regulatory elements of Eng17,22 as cells progressed from pre-hemangioblast 10 
mesoderm to hemangioblast mesoderm.  Eng expression increased by ~ 3-fold (Figure 1C)  11 
and enrichments of H3K9 acetylation (an active chromatin mark) increased  ~ 10-20 fold at 12 
the Eng promoter and -8kb, +7kb and +9kb Eng enhancers (Figure 1D).  There was no 13 
change in H3K9Ac at -4kb, a region that is highly conserved across species but shows no 14 
enhancer activity22.  15 
 16 
The Eng promoter when combined with the -8, +7 and +9 hemato-endothelial 17 
enhancers, targets FLK1+ mesodermal cells enriched for BL-CFC potential.  HM1 ESCs 18 
have a disrupted Hprt locus that can be reconstituted by homologous recombination of a 19 
targeting vector23.  They serve as a useful tool to evaluate reporter activity of single copies of 20 
gene regulatory elements at a constitutively active locus at different stages of ESC 21 
differentiation. We took advantage of this system to introduce combinations of Eng 22 
regulatory elements with blood and endothelial activity in in vivo transgenic assays (Figure 23 
S1). Successful recombination and generation of ESC lines with -8/P/lacZ, -8/P/lacZ/+7, -24 
8/P/lacZ/+9, -8/P/lacZ/+7/+9, -8/P/lacZ/+7Δ (GATA)/+9 and -8/P/lacZ/+7Δ (GATA)/+9 Δ 25 
12 
 
(ETS), was confirmed by RT-PCR and southern blotting (Figure S2). We used these ESC 1 
lines as a tool-kit with which to track, evaluate and compare the activity of each of these gene 2 
regulatory elements (GREs) during different stages of hematopoietic development and to 3 
fractionate cells for functional validation and transcriptomic analysis.   4 
  5 
To identify which, if any of the Eng GREs, targeted FLK1+ mesoderm enriched for 6 
hemangioblast potential, we generated embryoid bodies (EBs) from each ESC line and 7 
fractionated FLK1+lacZ- (F+L-) and FLK1+lacZ+ (F+L+) cells and performed blast colony 8 
forming cell (BL-CFC) assays (Figure 2A).  The Eng -8/P/lacZ/+7/+9 construct, which 9 
showed robust blood and endothelial staining in vivo17 targeted a fraction of the FLK1+ 10 
mesoderm that showed increased (~ 4 fold) BL-CFC potential (Figure 2B and Figure S3A). 11 
We have previously shown that mutating the GATA binding motifs in +7 and ETS binding 12 
motifs in +9 diminished endothelial activity and extinguished hematopoietic activity of the 13 
Eng -8/P/lacZ/+7/+9 construct in transgenic assays17. There was a corresponding reduction or 14 
failure of the mutant constructs to preferentially target cells with BL-CFC potential (Figure 15 
2C (i)-(ii) and Figure S3B). The -8P/lacZ construct showed strong endothelial but no 16 
hematopoietic activity in transgenic assays17. FLK1+ cells targeted by this construct (F+L+) 17 
showed significantly lower BL-CFC potential than F+L- cells (Figure 2D (i) and Figure 18 
S3A). For the -8P/lacZ/+7 and -8P/lacZ/+9 constructs, which showed strong endothelial and 19 
low- to moderate hematopoietic activity in in vivo transgenic assays17, FLK1+ mesoderm 20 
(F+L+) had either lower or equivalent BL-CFC activity than FLK1+ (F+L-) cells (Figure 2D 21 
(ii)-(iii) and Figure S3A).    It is important to note that the total number of BL-CFCs 22 
generated by FLK1+ mesoderm will vary from clone to clone but that comparisons are of 23 
BL-CFC potential of L+ and L- sorted FLK1+ cells from each clone. 24 
 25 
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 Taken together, these data show that the GREs of ENG that showed increased 1 
chromatin accessibility as pre-hemangioblast mesoderm progressed to hemangioblast 2 
mesoderm (i.e. -8/P/+7/+9; Figure 1D) act collectively to target reporter gene expression to 3 
BL-CFCs in FLK1+ mesoderm.  It is noteworthy that in in vivo transgenic assays, it was also 4 
this construct (-8/P/lacZ/+7/+9) that had the strongest and most specific activity in blood and 5 
endothelium in the developing embryo17. 6 
 7 
Global transcriptomic analysis of FLK1 mesoderm targeted by Eng -8/P/LacZ/+7/+9 8 
identifies genes associated with hemangioblast activity.  To discover genes associated with 9 
the activation of these GREs and increased activity of the reporters, we performed RNA-10 
sequencing on sorted lacZ+ and lacZ- cell fractions from three independent experiments.  As 11 
expected Kdr (Flk1) expression was comparable in both fractions and Eng transcripts were 12 
increased in the lacZ+ fraction consistent with Eng GRE driven reporter activity (Figure 3A).  13 
There was also a shared set of genes that was consistently differentially expressed between 14 
the lacZ+ and lacZ- cell fractions (Figure 3B (i)) and included 107 up-regulated and 101 15 
down-regulated genes.   These included cell surface receptors and transcription factors known 16 
to be associated with blood and endothelium (fold change ≥ 2 and p-value <0.5; Table S1 and 17 
Figure S4A) and genes that have been associated with hemangioblast development in the 18 
LifeMap Sciences embryonic development compendium (Figure 3B (ii)). Individually the 19 
expression of many genes known to be associated with early mesoderm (e.g. Bry/T and 20 
Bmp4), blood (e.g. Gata1 and Tal1) and endothelial (e.g. Foxc2 and Etv2) development did 21 
not vary significantly between these cell fractions (Figure 3B (ii)). Indeed, as hemangioblasts 22 
are a sub-population of FLK1+ mesoderm with multi-lineage differentiation potential, it 23 
would have been unusual to see significant differences in expression of individual genes that 24 
are strongly associated with commitment to a specific lineage.  However, ingenuity pathway 25 
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analysis (IPA) revealed that when differentially expressed genes were considered as a 1 
collective, there were strong associations with blood and blood vessel development for genes 2 
in the FLK1+/lacZ+ set (Figure S4B).  Consistent with these biological functions, this gene 3 
set also showed significant associations with signaling pathways that govern endothelial 4 
development and eNOS signaling (Figure S4C-F). 5 
 6 
To investigate the in vivo relevance of our gene set, we used GSEA analysis to 7 
compare expression overlaps with gene expression data from FLK1+ cells in ETV2 25,26 and 8 
LDB127 KO embryos, both of which are defective in hemangioblasts (Figure 3C). There were 9 
strong overlaps between genes expressed in FLK1+ mesoderm targeted by ENG -10 
8/P/lacZ/+7/+9 and genes expressed in hemangioblast competent WT ETV2 and LDB1 11 
embryos compared to ETV2+/- or LDB1-/- embryos respectively.  Therefore the molecular 12 
signature of BL-CFC enriched FLK1+ mesoderm that was identified using differential 13 
reporter activity of ENG GREs is consistent with in vivo functional capacity. 14 
 15 
The Eng promoter in combination with the -8 endothelial enhancer targets hemogenic 16 
endothelial cells enriched for hematopoietic potential.  Definitive hematopoiesis in the 17 
embryo progresses through a TIE2+/c-KIT+/CD41- hemogenic endothelial (HE) intermediate 18 
9
. We used a cell culture system that mirrors this in vivo transition to investigate whether any 19 
of the reporter ESC lines preferentially targeted HE cells and whether they could be used to 20 
isolate cell fractions that were enriched for hematopoietic potential9. To this end, FLK1+ 21 
cells were sorted from day 3EBs and seeded into liquid blast culture media (Figure 4A). At 22 
day 2 of culture, lacZ+ and lacZ- HE cells were isolated by FACS and re-seeded into liquid 23 
blast media (LBM) for two further days followed by flowcytometry and CFU-C assays to 24 
evaluate the hematopoietic potential of each fraction.  Of the reporter ESC lines, Eng -25 
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8/P/lacZ was unique in that it was active in a fraction of HE cells that generated more TIE2-1 
/CD41+ and CD45+ cells after 48 hours in culture (Figure 4B (i)- (ii)) and contained almost 2 
all CFU-C potential (Figure 4B (iii)). Whereas Eng -8/P/lacZ/+7/+9 targeted FLK1+ 3 
mesoderm with increased BL-CFC potential (Figure 2), it did not target HE cells with 4 
increased hematopoietic potential (Figure 4C (i) - (iii)). Indeed this and each of the other 5 
constructs, targeted HE cells that had lower hematopoietic potential (Figure 4D-E; Figure 6 
S5). Taken together, these data showed that not only was there a specific combination of 7 
ENG GREs that targeted HE cells but that the combination was distinct from that which 8 
targeted BL-CFCs in FLK1+ mesoderm. 9 
 10 
Hematopoietic potential is highest in Eng -8/P/lacZ targeted HE cells that do not as yet 11 
express surface ENG. Cell fate transitions are dynamic and our purpose was to use these 12 
reporter constructs to capture HE cells that were intrinsically fated towards the hematopoietic 13 
lineage at the earliest possible time point in culture.  Based on the assumption that there 14 
would be a delay between transactivating the Eng GRE reporter and surface expression of 15 
ENG, we repeated the experiments described in Figure 4 using the Eng -8/P/lacZ ES cell line 16 
but here also incorporating surface ENG expression to isolate TIE2+/C-KIT+/CD41- HE 17 
fractions that were ENG+/lacZ-, ENG+/lacZ+ or ENG-/lacZ+ (Figure 5A).  Interestingly, 18 
CFU-C potential within the lacZ+ fraction was highest in ENG-/lacZ+ HE cells (Figure 5B 19 
(i) – (ii)). ENG+/lacZ-, ENG+/lacZ+ and ENG-/lacZ+ HE cells were re-seeded in LBM and 20 
analysed by flow cytometry and CFU-C assays after two further days of culture.  The 21 
proportions of TIE2-/CD41+ (Figure 5C (i)) and CD45+ (Figure 5C (ii)) cells and CFU-C 22 
potential (Figure 5C (iii)) were highest for cultured ENG-/lacZ+ HE cells.  Taken together, 23 
these data show that the hematopoietic potential within HE cells can be targeted by Eng -24 
16 
 
8/P/lacZ and that these ESCs could be used to interrogate the earliest transcriptional changes 1 
associated with this cell fate decision. 2 
 3 
Transcriptomic analysis of HE fractions identifies genes associated with hemogenic 4 
endothelial to hematopoietic transition.    To discover genes, that act on Eng -8/P/lacZ and 5 
drive reporter gene activity and by extension are associated with hemogenic potential in 6 
TIE2+/C-KIT+/CD41- HE cells, we performed RNA-sequencing on sorted ENG+/lacZ-, 7 
ENG+/lacZ+ and ENG-/lacZ+ HE cell fractions from three independent experiments.  As 8 
expected the fractions, which expressed surface ENG had abundant Eng transcripts, which 9 
were still comparatively low in ENG-/lacZ+ HE cells (Figure 6A). Consistent with its role as 10 
a major determinant of endothelial to hematopoietic transition (EHT)9,24,28,  Runx1 transcripts 11 
were abundant in HE cells that were enriched with functional hemogenic cells (ENG-/lacZ+ 12 
HE) and relatively low in those (ENG+/lacZ- and ENG+/lacZ+ HE) that were not. In total, 13 
there were 707 up-regulated and 981 down-regulated genes in ENG-/lacZ+ HE cells 14 
compared with ENG+/lacZ- and ENG+/lacZ+ HE cells (Figure 6B (i); Table S2). It was 15 
interesting to note that only a subset of genes that have previously been attributed to mark HE 16 
cells based on cell surface protein expression were16 differentially expressed between these 17 
functionally distinct HE sub-populations (Figure 6B (ii)).  This does not imply that these 18 
genes are not important but that their higher or lower expression is not associated with these 19 
early subtle transitions. 20 
 21 
To investigate the in vivo relevance of our gene set, we used GSEA analysis to 22 
compare expression overlaps between ENG-/lacZ+ HE vs. ENG+/lacZ- HE and gene sets 23 
generated from primary embryonic endothelial cell (EC), hemogenic endothelial cells (HECs) 24 
and HSCs16. Consistent with our functional data, the gene sets associated with EC to HE 25 
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transition (Figure 6C (i) and HE to HSC transition (Figure 6C (ii)) showed strong overlaps 1 
with genes expressed in ENG-/lacZ+ HE.  Gene sets associated with HIF1a and DNA 2 
replication also showed strong overlaps with genes expressed in ENG-/lacZ+ HE cells 3 
(Figure S6A). Genes that were UP in ENG-/lacZ+ HE compared with ENG+/lacZ- HE cells 4 
feature prominently in IPA reconstructions of gene networks governing hematopoietic 5 
development (Figure S6B).  Whereas genes that were UP in ENG-/lacZ+ HE cells compared 6 
with either ENG+/lacZ- HE or ENG+/lacZ+ HE cells were associated with biological 7 
processes relating to blood development, genes that were DOWN in ENG-/lacZ+ HE cells 8 
relative to the other two fractions were associated more with angiogenesis or vasculogenesis 9 
(Figure S6C-E).  Interrogation of differentially expressed transcription factors (TFs) and cell 10 
surface receptors (CSRs) in the more functionally hemogenic ENG-/lacZ+ HE fraction 11 
relative to the ENG+/lacZ- HE fraction showed up-regulation of a number of TFs (e.g. 12 
Runx129, Myb30, Gfi1b31 etc.) and CSRs (Lgr532) that are known to play a role in HSC 13 
development and down regulation of others (e.g. Sox1733), which are important for HE to 14 
HSC transition (Figure 6D). 15 
 16 
Lrp2 is required for normal blood emergence in the zebrafish aorta. We then overlapped 17 
our gene sets to visualise associations between genes that were UP or DOWN in haemogenic 18 
mesoderm (HB) and/or hemogenic endothelium (HE) (Figure S7 and S8; Table S1-S2) to 19 
interrogate their function.   Six genes were shared between the up-regulated groups (Figure 20 
7A; Figure S7C) and eight genes between the down-regulated groups (Figure S8A).  Genes 21 
that were DOWN in both HB and HE cells included several with no known association with 22 
haematopoiesis (Figure S8B).  However, we focused on genes that were UP in both HB and 23 
HE cells (Figure 7A and S7C) for practical considerations given that their expression and 24 
functional role would be easier to validate. This group included hematopoietic transcription 25 
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factors (Gfi1 31 and Lyl134), a platelet protein kinase C substrate (Plek35) and granulocyte 1 
lysosomal and lysosomal membrane proteins (Mpo36 and Laptm537), all of which have known 2 
functions in the hematopoietic system.  It also included a multifunctional ligand (Lrp2) with 3 
no previously described role in blood or blood development. Lrp2/Megalin is a member of an 4 
endocytic receptor complex that is involved in maternal-fetal transport of folate and other 5 
nutrients, lipids and morphogens such as sonic hedgehog (Shh) and retinoids38.  Given these 6 
associations we postulated that Lrp2 up-regulation in blood precursors was likely to be of 7 
functional significance.  8 
 9 
 The Ly6aGFP (Sca1) mouse model, in which all HSCs throughout development are 10 
GFP+14,39 has facilitated the study of EHT. There mice were used to show in real-time, the 11 
transition of morphologically flat endothelial GFP+ cells in the E10.5 aorta to round GFP+ 12 
cells that co-express other HSC markers40.  Given that LRP2 was up-regulated in HE cells, 13 
we evaluated LRP2 expression in Ly6aGFP E10.5 AGM.  LRP2 shows specific expression in 14 
endothelial cells with strong expression in Ly6aGFP+ endothelial cells and hematopoietic 15 
clusters (Figure 7B).   16 
 17 
EHT is an evolutionarily conserved process in vertebrates and real-time imaging of 18 
transgenic zebrafish embryos has also shown the transition of aortic endothelial cells to 19 
hematopoietic cells41,42.  Lrp2 is highly conserved across different vertebrate species (Figure 20 
7C; average sequence identity across all species shown = 70 %).  The zebrafish genome has 21 
two closely related protein- coding genes, lrp2a on chr. 9 and lrp2b on chr. 12, both of which 22 
are expressed at 24-72hpf 43.  To validate the involvement of LRP2 in HSC generation, we 23 
used a zebrafish morpholino oligo (MO) knockdown approach targeting both lrp2a and 2b 24 
together and each alone. At 36h post fertilization (hpf), morphants were assayed by ISH for 25 
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cmyb and runx1, markers for emerging blood progenitors in the aorta44. WT embryos showed 1 
robust cmyb and runx1 expressing cells along the dorsal aorta in contrast to lrp2a/b 2 
morphants that showed severe reductions (Figure 7D (i); Figure S9A). There was partial 3 
rescue of AGM blood progenitors when lrp2a/b morphants were co-injected with hLRP2 4 
mRNA. The partial rescue was probably due to only partial homology of protein sequences 5 
between humans and fish (~ 65%) and quality of in vitro transcribed mRNA given the large 6 
size of LRP2 cDNA (~14kb).  To exclude non-specific toxicity related loss of cmyb and 7 
runx1 expressing cells, we co-injected lrp2a/b MO with tp53 MO and saw no restitution of 8 
cmyb expressing cells in the morphants (Figure S9B).  Injection of lrp2bMO but not 9 
lrp2aMO, reduced the numbers of cmyb expressing AGM blood progenitors (lrp2bMO; 10 
Figure 7D (ii); lrp2a; data not shown).  To establish that this defect in blood cell production 11 
was not a secondary to loss of vascular integrity, we injected lrp2a/b MO into flk:zsgreen 12 
transgenic embryos and saw no difference between morphants and controls at 32 hpf (Figure 13 
7E). In addition to vascular integrity we also assessed blood flow in morphants. Both heart 14 
function as well as blood flow was indistinguishable from control embryos (data not shown). 15 
Taken together these data support a role for LRP2 during AGM hematopoiesis. 16 
  17 
 18 
  19 
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DISCUSSION 1 
Regulatory elements of genes that demonstrate tissue specific expression have 2 
previously been used to target and characterise various cell populations in ESC systems45-48.  3 
They have also been used in conjunction with cell surface markers to isolate cell fractions at 4 
specific stages during embryonic development for the de novo discovery of regulators of 5 
hematopoiesis (e.g. Runx13 and Ly6a (Sca1)16).  These studies have in the main utilized 6 
reporter gene knock-in ESCs that disrupted a functional allele or transgenic mouse lines 7 
derived by pro-nuclear injections, which were subject to copy number and/or position effect 8 
variegation. Here we used a method to mitigate these caveats and leveraged prior knowledge 9 
that promoter/enhancer combinations of ENG specifically targeted endothelium or both blood 10 
and endothelium in the developing embryo17,22 to interrogate the transcriptomes of 11 
hemogenic progenitors.   12 
 13 
When initiating these experiments, we did not envisage that distinct combinations of 14 
ENG promoter/enhancers would target haemangioblast potential in FLK1 mesoderm and 15 
hemogenic potential in TIE2+/C-KIT+/CD41- hemogenic endothelium. In retrospect, given 16 
the distinct transcriptomes and functional properties of haemangioblasts and hemogenic 17 
endothelium, this should not have come as a surprise.  Nor did we predict that hemogenic 18 
potential would be enriched in ENG- HE1 cells targeted by the ENG -8PlacZ transgene.  19 
Given that F+L+ cells expressed higher levels of ENG (Figure 3A), these data raise the 20 
question whether HE1 cells emerge from F+L- ENG low cells which are less able than their 21 
F+L+ counterparts to generate BL-CFCs or whether F+L+ ENG high cells subsequently 22 
shutdown ENG expression to facilitate their haemogenic potential in HE1 cells. As these 23 
populations were targeted by different transgenes (F+L+; Eng-8/P/lacZ/+7/+9 and ENG-L+ 24 
HE; Eng-8/P/lacZ), this could not be directly tested. However, ES cells targeted with dual 25 
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reporters each driven by either Eng-8/P/+7/+9 or Eng-8/P may assist in addressing this 1 
specific question. 2 
 3 
Lrp2, a gene that encodes megalin, a multiligand uptake receptor that regulates 4 
circulating levels of diverse compounds49 emerged as a novel regulator of hematopoiesis.  5 
Mutations in LRP2 result in impaired neuro-epithelial development and are causative of 6 
Donnai-Barrow and facio-oculo-acoustico-renal syndromes50. It has been implicated in 7 
balancing BMP4 and SHH signaling in neuro-epithelium by acting as a clearance receptor for 8 
BMP4 and by concentrating or depleting SHH by ligand recycling or clearance respectively 9 
in a cell type and context dependent manner51. This is of mechanistic interest as the BMP4-10 
SHH gradient between the neural tube and dorsal aorta has also been implicated in the 11 
induction of the HSC developmental program in the ventral wall of the dorsal aorta52.  On a 12 
C57Bl/6N background the LRP2 mutation causes lethality in mice around the time of birth 13 
and there are no mutant pups although embryo collections at all embryonic stages to E18.5 14 
show expected Mendellian ratios. LRP2 mutations on 129 or CD1 backgrounds also do not 15 
yield survivors (Hammes et al, unpublished data). On a FVB/N background however, LRP2 16 
null mice are viable with neural tube defects and this receptor has previously been implicated 17 
in folate endocytosis in the developing neural tube53.  However, peripheral blood and bone 18 
marrow hematopoietic stem and progenitor cell numbers were comparable in FVB/N wild 19 
type and mutant adult mice at 6-9 months of age (Figure S10).  A more detailed analysis of 20 
embryonic hematopoiesis in mutant mice on both C57Bl/6N and FVB/N backgrounds will be 21 
required to establish whether the numbers of emergent HSCs differ at various time points and 22 
the identity of any modifier genes in FVB/N that compensate for the loss of LRP2 and these 23 
investigations are ongoing.  However, taken together with the zebrafish data, which shows 24 
reduction rather than loss of HSCs, LRP2 is likely to facilitate (or provide a fitness 25 
22 
 
advantage) rather than be absolutely required for EHT.  Indeed, it is important to keep in 1 
mind that Lrp2 transcripts were higher in HB cells with greater BL-CFC potential and HE 2 
cells with greater CFU-C potential but cells with lower numbers of transcripts were also able 3 
to generate BL-CFCs and CFU-Cs. 4 
 5 
Deficiency of dietary folate also results in impaired neural tube development and 6 
megaloblastic anemia54. Targeted inactivation of the reduced folate carrier (RFC1), which 7 
facilitates folate delivery into cells results in embryonic lethality at E10.5 due to neural and 8 
hematopoietic defects55 and components of the Megalin complex are amongst the most 9 
significantly disrupted genes in null embryos38.  Coordinated up-regulation of a receptor that 10 
facilitates folate uptake in hemogenic endothelial cells would be consistent with demand for 11 
an essential hematinic in cells that are on the threshold of a replicative phase.   12 
 13 
Although we focused our attention on Lrp2, as a gene without a described role in 14 
hematopoiesis, from a list of six that were up-regulated in both hemangioblasts and HE cells, 15 
there were other genes that were UP in only one or the other cell fraction. Given the overlap 16 
of these gene sets with those generated from gene knockout embryos that showed stage 17 
specific developmental defects or from sorted primary cells harvested from embryos, they 18 
will serve as a rich resource to explore and manipulate the emergence of hemangioblasts from 19 
FLK1+ mesoderm or definitive hematopoiesis in HE cells. Insights gained from these 20 
manipulations will in turn inform tissue regeneration protocols that aim to generate functional 21 
HSCs. 22 
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FIGURE LEGENDS 1 
FIGURE 1. Mesoderm to hemangioblast transition is accompanied by increased Eng 2 
expression and chromatin accessibility at hemato-endothelial regulatory elements. (A) 3 
Schematic representation of the ENG locus. The transcription start site is marked with an 4 
arrow. The -8kb, +7kb and +9kb enhancers and the promoter (P) are marked in orange, exons 5 
are marked in brown and the 5’UTR in cyan. (B) Schematic representation of Bry-GFP ES 6 
cell differentiation. At day 3 of EB differentiation, Bry-GFP+/FLK1- (G+F-) and Bry-7 
GFP+/FLK1+ (G+F+) cells were sorted and analysed by RT-PCR and ChIP.  (C) Bar graph 8 
showing Eng mRNA expression levels in sorted FLK1+ve and –ve mesodermal cell 9 
populations in day 3 EBs generated from Bry-GFP ES cells. (D)  A bar graph showing levels 10 
of enrichment of the active chromatin mark, H3K9Ac at Eng -8, P, +7 and +9 hemato-11 
endothelial enhancers relative to IgG in pre-hemangioblast mesoderm (G+F-; black) and in 12 
hemangioblast mesoderm (G+F+; gray).  Eng -4 was included as a negative control region. 13 
**; P < 0.01, ***; p < 0.001 14 
 15 
FIGURE 2.  The Eng promoter when combined with the -8, +7 and +9 haemato-16 
endothelial enhancers targets FLK1+ mesodermal cells enriched for BL-CFC potential. 17 
(A) Schematic representation of the experimental procedure. The Eng -8/P/LacZ, Eng -18 
8/P/LacZ/+7, Eng -8/P/LacZ/+9, Eng -8/P/LacZ/+7/+9, Eng -8/P/LacZ/+7Δ/+9, and Eng -19 
8/P/LacZ/+7Δ/+9Δ reporter constructs were introduced by homologous recombination into 20 
the HPRT locus of HM1 ES cells.  Recombinant clones were differentiated into day 3 EBs 21 
and stained for FLK1 expression and β-galactosidase activity. FLK1+/LacZ- (F+/L-; gray) 22 
and FLK1+/LacZ+ (F+/L+; blue) cells were sorted and seeded into BL-CFC assays. Fractions 23 
sorted from the Eng -8/P/LacZ/+7/+9 were further analysed by RNA-sequencing. (B) Flow 24 
cytometry profiles of Eng -8/P/LacZ/+7/+9 day 3 EBs (left). BL-CFCs from sorted F+/L- 25 
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(gray) and F+/L+ (blue) fractions. (C) (i) Flow cytometry profile of day 3 EBs derived from 1 
ES cells targeted with Eng -8/P/LacZ/+7Δ /+9 (mutated GATA motifs in the +7 enhancer) is 2 
shown to the left with corresponding BL-CFCs from sorted F+/L- (gray) and F+/L+ (blue) 3 
fractions shown to the right. (ii) Flow cytometry profile of day 3 EBs derived from ES cells 4 
targeted with Eng -8/P/LacZ/+7Δ /+9Δ (mutated GATA motifs in the +7 enhancer and 5 
mutated ETS motifs in the +9 enhancer) and corresponding BL-CFCs from sorted F+/L- 6 
(gray) and F+/L+ (blue) fractions.  (D) Flow cytometry profiles of day 3 EBs and BL-CFCs 7 
from sorted F+/L- (gray) and F+/L+ (blue) fractions are shown for ES cells targeted with (i) 8 
Eng -8/P/LacZ (ii) Eng -8/P/LacZ/+9 and (iii) Eng -8/P/LacZ/+7. BL-CFC counts are the 9 
total number of blast colonies generated from 2x104 seeded cells. Statistical analysis was 10 
using students T-test, *p<0.05, **p< 0.01. 11 
 12 
FIGURE 3. RNA-sequencing of FLK1 mesoderm targeted by Eng -8/P/LacZ/+7/+9 13 
identifies genes associated with hemangioblast activity. (A) RNA-sequencing profiles 14 
showing Kdr (Flk1) transcripts (top panel) and Eng transcripts (bottom panel) in the F+/L- 15 
and F+/L+ fractions. FPKM expression values are shown to the right. (B) (i) Heat map 16 
representation of up- and down-regulated genes in FLK1+/LacZ- (F+/L-) and FLK1+/LacZ+ 17 
(F+/L+) fractions in three independent experiments. (ii) Expression (FPKM values) levels of 18 
genes that have previously been associated with hemangioblast function. The left panel 19 
shows a subset of genes that are differentially expressed between F+/L- and F+/L+ fractions 20 
and the right panel shows a subset of genes that are not.  (C) GSEA profiles showing the 21 
correspondence of genes that are differentially expressed between F+/L- and F+/L+ fractions 22 
and  those that are differentially expressed in ETV2+/- vs. ETV2-/- (top panel) and LDB wt 23 
vs. LDB -/- gene sets. DEG; differentially expressed genes. 24 
 25 
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FIGURE 4. The Eng promoter in combination with the -8 endothelial enhancer targets 1 
hemogenic endothelial cells enriched for hematopoietic potential. (A) Schematic diagram 2 
outlining the experimental procedure.  Recombinant ES cells generated using the Eng 3 
reporter constructs were differentiated into day 3 EBs. FLK1+ mesodermal cells were sorted 4 
from representative clones for each recombinant ES cell line and cultured in liquid blast 5 
media. At 48 hours, CD41-/TIE2+/c-KIT+ (HE) cells were sorted into lacZ+ and lacZ– 6 
fractions. The sorted fractions were re-cultured in liquid blast media for a further 48 hours 7 
followed by flow cytometry and CFU-C assays. (B) (i) CD41 and TIE2 expression in sorted  8 
c-KIT+ HE LacZ- (white) and LacZ+ (blue) fractions (after 2 days of re-culture) derived 9 
from Eng -8/P/LacZ ES cells. (ii) Percentage of CD45+ cells generated from LacZ- and 10 
LacZ+ HE fractions. (iii) Bar chart showing the number and type of hematopoietic colonies 11 
generated by each fraction.  (C) (i)-(iii) Corresponding data to (B) generated from Eng -12 
8/P/LacZ/+7/+9 ES cells. (D) (i)-(iii) Corresponding data to (B) generated from Eng -13 
8/P/LacZ/+7 ES cells. (E) (i)-(iii) Corresponding data to (B) generated from Eng -14 
8/P/LacZ/+9 ES cells.  Primitive and definitive colonies were scored after four and nine days 15 
respectively. Statistical analysis was using students T-test, *; p<0.05, **; p< 0.01. 16 
 17 
FIGURE 5. Hematopoietic potential is highest in Eng -8/P/lacZ targeted HE cells that 18 
do not express surface ENG.  (A) Schematic diagram outlining the experimental procedure.  19 
FLK1+ mesodermal cells were sorted from day 3 EBs generated from the Eng -8/P/LacZ 20 
recombinant ES cell line and cultured in liquid blast culture media. At 48 hours, CD41-21 
/TIE2+/c-KIT+ (HE) cells were sorted into ENG+/LacZ-, ENG+/LacZ+, and ENG-/LacZ+ 22 
fractions. These fractions were either directly seeded into CFU-C assays (B) or re-cultured in 23 
liquid blast media for a further 48 hours and analysed by flow cytometry and CFU-C assays 24 
(C). (B) (i)- (ii) Flow cytometry to show the frequencies of CD41-/TIE2+/c-KIT+ (HE) cells 25 
30 
 
in  ENG+/lacZ+, ENG+/lacZ- and ENG-lacZ+ fractions. (iii) CFU-C potential of each sorted 1 
fractions in (i). (C) (i) Flow cytometry analysis of CD41 and TIE2 expression in sorted HE 2 
cell fractions after two days of re-culture in liquid blast media. (ii)  Bar chart showing the 3 
percentage of CD45 positive cells in sorted fraction. (iii)  Bar chart showing hematopoietic 4 
colony numbers from each fraction.  Primitive and definitive colonies were scored after four 5 
and nine days respectively. Statistical analysis was using student T-test, *; p < 0.05, **; p 6 
<0.01 and ***; p <0.001. 7 
 8 
FIGURE 6. Transcriptomic analysis of HE fractions identifies genes associated with 9 
hemogenic endothelial to hematopoietic transition.  (A) RNA-sequencing profiles showing 10 
Eng transcripts (top panel) and  Runx1 transcripts (bottom panel) in the E+/L-, E+/L+ and E-11 
/L+ fractions. FPKM expression values are shown to the right. (B) (i) Heat map 12 
representation of up- and down-regulated genes in ENG+/LacZ- (E+/L-) HE, ENG+/LacZ+ 13 
(E+/L+) HE and ENG-/LacZ+ (E-/L+) HE fractions in three independent experiments. (ii) 14 
Expression (FPKM values) levels of genes that have previously been associated with 15 
hemogenic endothelium. The top panel shows a subset of genes that are differentially 16 
expressed between E+/L-, E+/L+ and E-/L+ fractions and the bottom panel shows a subset of 17 
genes that are not.  (C) GSEA profiles showing the correspondence of genes that are 18 
differentially expressed between the E+/L-, E+/L+ and E-/L+ fractions and  those that are 19 
differentially expressed in endothelial cells (EC) vs. hemogenic endothelial cells (HEC) (top 20 
panel) and HECs vs. hematopoietic stem cells (HSC) gene sets.  (D) Transcription factors and 21 
cell surface receptors that are up- and down regulated in the Eng -8/P E-/L+ HE fraction. The 22 
log fold changes (logFC) and log false discovery rates (logFDR) are listed for each gene. 23 
DEG; differentially expressed genes.  24 
 25 
31 
 
FIGURE 7. Lrp2 is required for normal definitive hematopoiesis. (A) Venn diagram 1 
showing the overlap of genes that are UP in FLK1 mesoderm enriched for BL-CFCs and/or 2 
HE cells enriched for hemogenic potential.  (B) Immunohistochemistry of 3 
E10.5 Ly6aGFP AGM shows co-expression of GFP and LRP2 in endothelial cells and 4 
hematopoietic clusters.  The insets show the same sections at low magnification. (C) 5 
Homology relationships of zebrafish lrp2a and lrp2b coding sequences with that of Lrp2 in 6 
different vertebrate species.  (D) ISH for the HSC marker cmyb in zebrafish at 36 hpf. (i) 7 
Low (left-side panels) and high (right-side panels) magnification images of control zebrafish 8 
(top row), lrp2 a/b morpholinos (middle row) and lrp2a/b morpholinos co-injected with 9 
hLRP2 mRNA (bottom row) zebrafish. (ii) Low (left-side panels) and high (right-side panels) 10 
magnification images of control zebrafish (top row) and lrp2b morpholinos. (E) Confocal 11 
images of flk:zsgreen reporter embryos show an intact vasculature in both control (upper 12 
panel) and lrp2a/b morphant (lower panel) embryos. DA; dorsal aorta, NC; notochord, NT; 13 
neural tube. 14 
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